whatpeptidestostack
← Compound library
SLU-PP-332
A synthetic exercise mimetic studied in mice for metabolism, heart failure and kidney aging. No human has been given it in this set.
The basics
| Human protocol on record | None published |
|---|---|
| Animal or laboratory figures | 5 |
| Published records retrieved | 10 |
| Registered trials | 0 |
| Certificate of analysis | Published by the partner |
| Regulatory status | Research-grade material, no approved human use |
1. The protocol on record
Hard disclaimer. Figures below are transcribed from a published study or an approved label exactly as the source states them. They record what researchers administered in a trial population, not instructions for any person, and none of it is adjusted to you. Most compounds here have no approved human use. Do not act on any of it without a licensed prescriber who knows your history.
Amounts and schedules, human record
No published human protocol exists for SLU-PP-332 in the cited record. No amount, frequency or schedule can be given here without inventing it, and this page does not invent figures.
Animal and laboratory models (not human figures)
| Phase or model | Amount | Frequency | Timing | Route | Duration | Source |
|---|---|---|---|---|---|---|
| Mouse obesity and metabolic-syndrome model (diet-induced obese or ob/ob mice) | not stated | not stated | not stated | not stated | not stated | source |
| Mouse aging-kidney model (21-month-old mice) | not stated | not stated | not stated | not stated | 8 weeks | source |
| Mouse exercise-endurance model | not stated | not stated | not stated | not stated | not stated | source |
| Mouse pressure overload-induced heart failure model (6-week pressure overload) | not stated | not stated | not stated | not stated | not stated | source |
| Mouse exercise-capacity study, SLU-PP-332 compared with SLU-PP-915 | not stated | not stated | not stated | intraperitoneal | not stated | source |
Half-life and why the schedule looks like that
Not stated in the cited record. No half-life, clearance figure, or duration of action is given in any cited source, and no dosing frequency is stated for any animal model. The pharmacokinetic statements the record does contain are limited to these: - The identification study reports that SLU-PP-332 "has sufficient pharmacokinetic properties to be used as an in vivo chemical tool," without giving any half-life or clearance value (PMID 36988910). - A follow-up study on the related compound SLU-PP-915 states that SLU-PP-332 "lacks oral bioavailability" and was administered intraperitoneally in the mouse comparison study (PMID 41421047). Because no half-life and no frequency are published, no sc
Handling and storage
- Lyophilised storage: Not stated in the cited record. - Storage after reconstitution: Not stated in the cited record. - Temperature: Not stated in the cited record. - Light: Not stated in the cited record. - Stability duration: Not stated in the cited record. No approved label exists for this compound, so there is no label storage guidance to cite.
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Open the interactive builder for reconstitution maths and a calendar →
2. Safety and harm reduction
Reported adverse effects
No adverse effects are reported in the cited record for SLU-PP-332. That is an absence of published reporting, not evidence of safety.
Cautions stated in the literature
- No human clinical trials of SLU-PP-332 exist in the cited record; the 2026 systematic review states that clinical trials are needed to confirm efficacy and safety in humans (PMID 42024694).
- The World Anti-Doping Agency (WADA) prohibits the use of exercise mimetics and metabolic modulators in sports, a category that covers SLU-PP-332; two doping-control studies were published specifically to enable detection of its misuse (PMID 41688415, PMID 41588687).
- SLU-PP-332 lacks oral bioavailability, and the cited work was performed by intraperitoneal injection in mice; the record does not establish any safe or effective human route (PMID 41421047).
Stop and get help
- Any severe or worsening reaction after administration.
- Signs of an allergic reaction, such as rash, swelling, or difficulty breathing.
- Signs of injection-site infection, such as spreading redness, warmth, pain, or discharge.
- Anything unexpected and persistent.
Pairings
Co-studied
Glutathione and SLU-PP-332
These two appear in one laboratory study, but only because glutathione was measured as a readout while cells were treated with SLU-PP-332.
Open the pairing brief →SLU-PP-332 at Peptara Labs
Open the SLU-PP-332 pageRead the third-party certificate of analysis before anything else. Research-grade material, research use only.